Chari, A; Samur, MK; Martinez-Lopez, J; Cook, G; Biran, N; Yong, KL; Hungria, VTDM; ... Avet-Loiseau, H; + view all Chari, A; Samur, MK; Martinez-Lopez, J; Cook, G; Biran, N; Yong, KL; Hungria, VTDM; Engelhardt, M; Gay, F; Garcia-Feria, A; Oliva, S; Oostvogels, R; Gozzetti, A; Rosenbaum, CA; Kumar, SK; Stadtmauer, E; Einsele, H; Beksac, M; Weisel, KC; Anderson, KC; Mateos, M-V; Moreau, P; San Miguel, J; Munshi, NC; Avet-Loiseau, H; - view fewer (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood , 136 (26) pp. 3033-3040. 10.1182/blood.2020008150.

Preview

Text blood.2020008150.pdf - Accepted Version Download (1MB) | Preview

Abstract

The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item